{"commentary":{"count":72,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":48,"youtube":12,"podcast":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02680587\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ORIOLE","nct_id":"NCT02680587","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oriole-nct02680587. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ORIOLE","arms":[{"description":"Men with oligometastatic prostate cancer lesions randomized to observation","label":"Observational (no SBRT)","type":"NO_INTERVENTION"},{"description":"Men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).","label":"SBRT","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2022-10-31","type":"ACTUAL"},"conditions":["Prostate Cancer","Oligometastases"],"enrollment":{"count":80,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"SBRT","type":"RADIATION"}],"last_update":"2022-11-29","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","official_title":"Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-08-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression at 6 Months","timeFrame":"6 months"}],"references":[{"citation":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147.","pmid":"32215577","type":"BACKGROUND"},{"citation":"Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.","pmid":"28662647","type":"BACKGROUND"},{"citation":"Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, Fodor C, Netti S, Zerini D, Luzzago S, Mistretta FA, Venetis K, Cursano G, Burla T, Mazzocco K, Cattani F, Petralia G, Fusco N, Pravettoni G, Musi G, De Cobelli O, Tang C, Ost P, Palma DA, Orecchia R, Jereczek-Fossa BA. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025 Mar;26(3):300-311. doi: 10.1016/S1470-2045(24)00730-7.","pmid":"40049196","type":"DERIVED"},{"citation":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24.","pmid":"36001857","type":"DERIVED"}],"start_date":{"date":"2016-04-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiation for Prostate Oligometastases","url":"https://clinicaltrials.gov/study/NCT02680587"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oriole-nct02680587"}